News | January 14, 2007

Ad Campaign Aims at SCA Awareness

Jan. 15, 2007 — Medtronic, Inc. announced today its launch of a national campaign designed to raise awareness of sudden cardiac arrest (SCA), its risk factors, and the role of implantable cardioverter-defibrillator (ICD) therapy in saving lives. SCA is the one of the nation's leading causes of death -- claiming more lives than breast cancer, lung cancer, and HIV/AIDS combined.

"Today, nearly 1,000 Americans will die of sudden cardiac arrest — many of these deaths could have been prevented with ICD therapy," said Steve Mahle, president of Cardiac Rhythm Disease Management at Medtronic. "We believe that more can be done to reach the hundreds of thousands of people who we know could benefit from ICD therapy, but remain unprotected. Ultimately, we believe this campaign will help save more lives."

The comprehensive campaign includes advertising; patient and caregiver information resources; physician education programs and outreach; and ongoing clinical research on SCA and the use of ICD therapy. The advertising begins this week with the launch of print, television and online advertising in the U.S.
The ads, themed "What's Inside," show the link between medical device technology and the benefits people can experience by living with ICD therapy. The ads encourage those who may be at greatest risk of SCA — people who have had a heart attack or been diagnosed with heart failure — to visit www.whatsinside.com or call 866-950-5550 for more information, including an SCA risk assessment that can be used to facilitate a discussion with a physician.

Sudden cardiac arrest is a sudden, abrupt loss of heart function — it is 95 percent fatal if left untreated, the company stated. Most SCA episodes are caused by the rapid and/or chaotic activity of the heart known as ventricular tachycardia (VT) or ventricular fibrillation (VF). Recent estimates show that approximately 850,000 people in the U.S. are at risk of SCA and indicated for an ICD device, but remain unprotected. In fact, less than 35 percent of patients who are indicated for an ICD have one.


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

Sept. 2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter ...

Home September 05, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
Subscribe Now